- US Listing of Aladdin shares planned to start in late October
- The innovative expertise of MCAP matches perfectly Aladdin´s needs within the US stock market
- Cooperation with US pioneering electronic market maker enhances liquidity of the shares
BERLIN/LONDON, September 15, 2020 – Aladdin Healthcare Technologies SE (“Aladdin”, ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, has signed an agreement with MCAP LLC in order to realize the electronic market making of its shares on the OTCQX market and get the necessary broking services for the US listing.
MCAP LLC is a leading US-based financial technology developer, electronic market maker and global securities markets operator. MCAP’s digital trading technologies connect institutional investors and companies to the global equity and fixed income markets, including American Depository Receipts (ADRs), Foreign Ordinary Shares, US Treasuries, Corporates, Mortgage Backed Securities, ETFs and money market instruments.
In August, Aladdin already announced its qualification to trade on the top tier OTCQX market, maintaining its listing on the Düsseldorf and the Frankfurt Stock Exchange. The US listing is planned to start in late October this year and will enhance the availability and profile of Aladdin shares to the international investing community, by entering the US stock market, namely the world´s largest capital market for healthcare technology.
Being accompanied by a pioneering financial technology developer like MCAP LLC, Aladdin will be able to improve the availability and liquidity of its shares and be present on the stock market at a more international level.
Wade Menpes-Smith comments: “We are excited to be working with a technology-focused company and believe this is a perfect match for our financial services needs within the US market bringing further liquidity to the Aladdin shares via MCAP’s proprietary platforms.”
More information about MCAP LLC can be found at: https://www.mcapmarkets.com/.
About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets aged related disease including a significant focus on Alzheimer’s disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose aged related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used to by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.
Website Link: www.aladdinid.com
TICKER SYMBOL: NMI
For further information
Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696
CROSS ALLIANCE communication GmbH
Phone +49 89 1250 90330